晓伟 马

Xiaowei Ma has a solid work experience in the pharmaceutical industry. 晓伟 started their career in 2012 as a DMPK study director at Shanghai Pharmaking. 晓伟 then took on a similar role at Natong Sincere Pharmaceutical from 2016 to 2017. In 2017, they joined Jiangsu Hansoh Pharmaceutical Group as a Scientist and worked there until 2019. During this time, they gained experience in protocol and clinical study report drafting and participated in IND documentation. In 2019, they became a Scientist at NewBio Therapeutics, Inc. for a short period before joining Reistone Biopharma as a DMPK manager. Overall, Xiaowei Ma has consistently held positions of increasing responsibility in the pharmaceutical field.

晓伟 马 attended Shenyang Pharmaceutical University from 2009 to 2012, where they earned a Bachelor's degree in Pharmaceutical Analysis. Additionally, they also attended Harbin University of Commerce, although the specific years of attendance and degree obtained are unknown. At Harbin University of Commerce, their field of study was Pharmaceutical Engineering.